Congratulations!

[Valid RSS] This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

Source: https://international-pharma.com/feed/

  1. <?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
  2. xmlns:content="http://purl.org/rss/1.0/modules/content/"
  3. xmlns:wfw="http://wellformedweb.org/CommentAPI/"
  4. xmlns:dc="http://purl.org/dc/elements/1.1/"
  5. xmlns:atom="http://www.w3.org/2005/Atom"
  6. xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
  7. xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
  8. xmlns:media="http://search.yahoo.com/mrss/" >
  9.  
  10. <channel>
  11. <title>International Pharmaceutical Industry</title>
  12. <atom:link href="https://international-pharma.com/feed/" rel="self" type="application/rss+xml" />
  13. <link>https://international-pharma.com</link>
  14. <description>Peer Reviewed, Contemporary, Authoritative</description>
  15. <lastBuildDate>Thu, 28 Mar 2024 09:51:43 +0000</lastBuildDate>
  16. <language>en-GB</language>
  17. <sy:updatePeriod>
  18. hourly </sy:updatePeriod>
  19. <sy:updateFrequency>
  20. 1 </sy:updateFrequency>
  21. <generator>https://wordpress.org/?v=6.4.3</generator>
  22.  
  23. <image>
  24. <url>https://international-pharma.com/wp-content/uploads/2022/01/Favicon-IPI-150x150.png</url>
  25. <title>International Pharmaceutical Industry</title>
  26. <link>https://international-pharma.com</link>
  27. <width>32</width>
  28. <height>32</height>
  29. </image>
  30. <item>
  31. <title>Stäubli Robotics invites the pharmaceutical industry: MOVE on with your automation upgrade</title>
  32. <link>https://international-pharma.com/staubli-robotics-invites-the-pharmaceutical-industry-move-on-with-your-automation-upgrade/</link>
  33. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  34. <pubDate>Thu, 28 Mar 2024 09:48:03 +0000</pubDate>
  35. <category><![CDATA[News]]></category>
  36. <guid isPermaLink="false">https://international-pharma.com/?p=38768</guid>
  37.  
  38. <description><![CDATA[Stäubli Robotics to show automation solutions for all GMP grades at ACHEMA 2024 ACHEMA, a global forum for process industries, is coming to Frankfurt am Main, Germany on June 10 &#8211; 14, showcasing process solutions for chemical, pharmaceutical, and biotech research and manufacturing. As organizations prepare for automation upgrades, Stäubli Robotics, a leader in industrial [&#8230;]]]></description>
  39. <content:encoded><![CDATA[
  40. <p><em>Stäubli Robotics to show automation solutions for all GMP grades at ACHEMA 2024</em></p>
  41.  
  42.  
  43.  
  44. <p><strong>ACHEMA, a global forum for process industries, is coming to Frankfurt am Main, Germany on June 10 &#8211; 14, showcasing process solutions for chemical, pharmaceutical, and biotech research and manufacturing. As organizations prepare for automation upgrades, <a>Stäubli</a> Robotics, a leader in industrial automation, comes prepared with a robust portfolio of pharmaceutical robots designed to address the requirements of each GMP clean air grade. Visitors can see Stäubli’s exhibits and live demonstrations at Booth J72, Hall 3.1.</strong></p>
  45.  
  46.  
  47.  
  48. <p>Robots in the pharmaceutical industry must meet strict criteria beyond the requirements of most other industries. The focus is on cleanability and compatibility with decontamination media and processes as defined by GMP grades. Stäubli Robotics brings leading-edge automation solutions to each area of production with robots engineered to meet the requirements of isolators, RABs, and freeze dryers in Grade A/B areas as well as less restricted Grade C/D areas.</p>
  49.  
  50.  
  51.  
  52. <p>ACHEMA attendees will have the opportunity to discover Stäubli’s complete pharma offering, comprised of three distinct robot ranges – the newest, accessPharma, for non-aseptic applications; Stericlean for aseptic applications; and Stericlean+ for use in isolators – covering the full spectrum of requirements. At Booth J72, Hall 3.1., Stäubli will exhibit three next-level pharma robots, representing each product range: a TX2-90 accessPharma, a TX2-60 Stericlean, and a TX2-60 Stericlean+.</p>
  53.  
  54.  
  55.  
  56. <p><strong>Grade A/B to C/D: Product evolution for changing industry demands</strong></p>
  57.  
  58.  
  59.  
  60. <p>Stäubli has been a partner to the pharmaceutical industry for decades. Its groundbreaking Stericlean series, launched in 2008, was the world’s first robot designed to operate in areas with rigorous cleaning procedures. They have since been deployed in pharmaceutical and biotech labs and production facilities worldwide, where they bring new levels of efficiency to material handling, fill-finish, and many other applications. The current era, defined by new market challenges and stricter regulations such as the revised GMP Annex 1, requires solutions that can stand up to heightened regulatory scrutiny while elevating efficiency and increasing output. Building on the long success of the acclaimed Stericlean, Stäubli worked with OEMs, system integrators, and customers in the pharmaceutical </p>
  61.  
  62.  
  63.  
  64. <p>space to expand and adapt its robots to handle more applications and meet changing compliance and commercial needs. The result is Stericlean+, which debuted in 2022 with the flagship TX2-60.</p>
  65.  
  66.  
  67.  
  68. <p>Stericlean+ is a breakthrough in the automation of highly aseptic processes, featuring higher cleanability, a new FDA-compliant surface coating and joint sealings, and other enhanced hygienic design features aimed at delivering unprecedented levels of product and patient safety. The entire outer surface is capable of withstanding intensive cleaning and decontamination with VHP (H2O2) in isolators.</p>
  69.  
  70.  
  71.  
  72. <p>Together, Stericlean and Stericlean+ cover all requirements in Grade A/B production areas, meeting the highest hygiene and cleanliness standards in isolators, RABs, freeze dryers, and autoclaves. They are also used in cell &amp; gene therapy (CGT), biotherapy, API research and production, lab automation, auxiliary processes, and other areas within pharmaceuticals.</p>
  73.  
  74.  
  75.  
  76. <p><strong>Bringing optimal automation to the Grade C environment</strong></p>
  77.  
  78.  
  79.  
  80. <p>The newest pharma offering from Stäubli, accessPharma, focuses on the Grade C environment, coming full circle with fast, reliable automation solutions for non-aseptic areas. The accessPharma series is designed for inspection and secondary packaging applications in Grade C/D areas, where cleaning is generally handled with isopropyl alcohol or ethanol alcoholic wipes. The robots feature a new isopropyl alcohol- and ethanol-resistant coating, as well as hygienic screws.</p>
  81.  
  82.  
  83.  
  84. <p>Automation upgrades in Grade C areas can help organizations cope with labor shortages and relieve workers of the physical demands of loading and unloading machines. They also support regulatory compliance and help ensure consistent workflow and throughput.</p>
  85.  
  86.  
  87.  
  88. <p><strong>Stericlean+ demos and exhibits bring aseptic automation upgrades to life</strong></p>
  89.  
  90.  
  91.  
  92. <p>Minimizing human intervention is always a major theme in pharmaceutical industry automation. The revised Annex 1 specifically emphasizes the need to reduce human intervention in aseptic processes and increase automation to lower the risk of contamination while scaling production.</p>
  93.  
  94.  
  95.  
  96. <p>Automation and robots have long been the norm in Grade A/B areas, where product containers remain open, and the risk of contamination is high. However, open systems that allow manual fault intervention via glove ports continue to pose risks. Annex 1 discourages the use of glove ports, accelerating the trend toward closed automated systems with gloveless isolators. In such systems, the same robots that perform process tasks can handle fault interventions with the use of telemanipulation, thereby eliminating the risks.</p>
  97.  
  98.  
  99.  
  100. <p>In an interactive exhibit at ACHEMA, attendees will have the opportunity to test Stäubli’s telemanipulation functionality hands-on, moving a TX2-60 Stericlean+ robot with an optional hollow wrist using a joystick rather than gloved hands – a technological advancement that promises to propel the industry forward in its evolution.</p>
  101.  
  102.  
  103.  
  104. <p><strong>Automating the gap between fill-finish and freeze dryer</strong></p>
  105.  
  106.  
  107.  
  108. <p>A look at the set-up of pharmaceutical production lines, particularly fill-finish machines and freeze dryers, can reveal key trends in automation. In new plants, these stations are usually arranged close to one another. This is not always the case at existing plants that require automation upgrades; therefore, automating transportation from the end of the fill-finish line to the freeze dryer is currently a major focus of automation upgrades.</p>
  109.  
  110.  
  111.  
  112. <p>Traditionally, product containers are moved between filling and freeze drying stations either by conveyors or humans. But a more efficient and safer alternative is on the horizon: automated guided vehicles (AGVs) adapted to the aseptic requirements of Grade A/B environments. Serving as a link between these cells, a mobile solution could be the key to meeting aseptic process requirements while increasing production.</p>
  113.  
  114.  
  115.  
  116. <p>According to Rudolf M. Weiss, Global Head of Life Sciences &amp; Food at Stäubli Robotics, “We continuously develop robotic solutions for all applications and cleanroom levels in the life science sector, but the spotlight will be on hygienic design mobile robots for highly demanding mobile applications in Grade A/B environments, where rigorous cleaning requirements apply.”</p>
  117.  
  118.  
  119.  
  120. <p>Stäubli’s pharma robots are already a major asset on fill-finish lines. ACHEMA attendees can witness this for themselves at Stäubli’s freeze dryer loading/unloading demo cell, developed in partnership with Spanish company Telstar, a specialist in pharmaceutical process equipment. The demo features a stationary Grade A-compliant TX2-90 Stericlean+ robot loading trays into a “pizza door” freeze dryer and handling auxiliary tasks such as picking up clips and linking the trays to each other.</p>
  121.  
  122.  
  123. <div class="wp-block-image">
  124. <figure class="aligncenter size-large"><img fetchpriority="high" decoding="async" width="1024" height="512" src="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_SmallLiquidProductionPackaging-1024x512.jpg" alt="" class="wp-image-38769" srcset="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_SmallLiquidProductionPackaging-1024x512.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_SmallLiquidProductionPackaging-300x150.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_SmallLiquidProductionPackaging-768x384.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_SmallLiquidProductionPackaging-1536x768.jpg 1536w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_SmallLiquidProductionPackaging-2048x1024.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Final packaging Grade D/E &amp; CNC (ISO 8) Driven by the emergence of mobile solutions, integrating automation into the final production tasks, currently handled by humans, is an ongoing project at pharma factories.</figcaption></figure></div>
  125.  
  126. <div class="wp-block-image">
  127. <figure class="aligncenter size-large"><img decoding="async" width="1024" height="512" src="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_AuxiliaryProcess-1024x512.jpg" alt="" class="wp-image-38770" srcset="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_AuxiliaryProcess-1024x512.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_AuxiliaryProcess-300x150.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_AuxiliaryProcess-768x384.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_AuxiliaryProcess-1536x768.jpg 1536w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_AuxiliaryProcess-2048x1024.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Grade A/B (ISO 5) Existing pharmaceutical production lines reveal key trends in automation. Therefore, automating transportation from the end of the fill-finish line to the freeze-dryer is currently a major focus of automation upgrades.</figcaption></figure></div>
  128.  
  129.  
  130. <figure class="wp-block-image size-large"><img decoding="async" width="1024" height="614" src="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_PackMaterial-1024x614.jpg" alt="" class="wp-image-38771" srcset="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_PackMaterial-1024x614.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_PackMaterial-300x180.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_PackMaterial-768x461.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_PackMaterial-1536x922.jpg 1536w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_PackMaterial-2048x1229.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Container production: The amount of containers for drug delivery is constantly growing. This production phase offers big automation opportunities from glass tube handling, loading/unloading, washing and siliconization, assembly to palettizing.</figcaption></figure>
  131.  
  132.  
  133. <div class="wp-block-image">
  134. <figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="512" src="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_LiquidProduction-1024x512.jpg" alt="" class="wp-image-38772" srcset="https://international-pharma.com/wp-content/uploads/2024/03/Pharma_LiquidProduction-1024x512.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_LiquidProduction-300x150.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_LiquidProduction-768x384.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_LiquidProduction-1536x768.jpg 1536w, https://international-pharma.com/wp-content/uploads/2024/03/Pharma_LiquidProduction-2048x1024.jpg 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Grade A (ISO 5) Robotics in containment isolators. The trend toward gloveless isolators will encourage the wider use of 6-axis robots for both repetitive and unplanned tasks.</figcaption></figure></div>
  135.  
  136. <div class="wp-block-image">
  137. <figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="614" src="https://international-pharma.com/wp-content/uploads/2024/03/TX2-40_accessPharma-1024x614.png" alt="" class="wp-image-38773" srcset="https://international-pharma.com/wp-content/uploads/2024/03/TX2-40_accessPharma-1024x614.png 1024w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-40_accessPharma-300x180.png 300w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-40_accessPharma-768x461.png 768w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-40_accessPharma-1536x922.png 1536w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-40_accessPharma-2048x1229.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">TX2-40 accessPharma: The newest accessPharma series is designed for inspection and secondary and packaging applications in Grade C/D areas. or ind secondary packaging applications in Grade C/D areasection and secondary packaging applications in Grade C/D areas</figcaption></figure></div>
  138.  
  139. <div class="wp-block-image">
  140. <figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="614" src="https://international-pharma.com/wp-content/uploads/2024/03/TX2-60_Stericlean-1024x614.png" alt="" class="wp-image-38774" srcset="https://international-pharma.com/wp-content/uploads/2024/03/TX2-60_Stericlean-1024x614.png 1024w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-60_Stericlean-300x180.png 300w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-60_Stericlean-768x461.png 768w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-60_Stericlean-1536x922.png 1536w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-60_Stericlean-2048x1229.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">TX2-60 Stericlean+: for use in isolators in Grade A highly aseptic areas</figcaption></figure></div>
  141.  
  142. <div class="wp-block-image">
  143. <figure class="aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="717" height="1024" src="https://international-pharma.com/wp-content/uploads/2024/03/TX2-90_Stericlean-717x1024.png" alt="" class="wp-image-38775" style="width:256px;height:auto" srcset="https://international-pharma.com/wp-content/uploads/2024/03/TX2-90_Stericlean-717x1024.png 717w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-90_Stericlean-210x300.png 210w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-90_Stericlean-768x1097.png 768w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-90_Stericlean-1075x1536.png 1075w, https://international-pharma.com/wp-content/uploads/2024/03/TX2-90_Stericlean-1434x2048.png 1434w" sizes="(max-width: 717px) 100vw, 717px" /><figcaption class="wp-element-caption">TX2-90 Stericlean: Stericlean series for aseptic applications in Grade A/B areas meeting hygienic and cleanliness standards. Designed for RABs and freeze dryers.</figcaption></figure></div>
  144.  
  145.  
  146. <p></p>
  147.  
  148.  
  149.  
  150. <p><strong>For more information, please contact:<br></strong></p>
  151.  
  152.  
  153.  
  154. <p><a>Sonja Koban</a></p>
  155.  
  156.  
  157.  
  158. <p>Global Event Marketing Manager</p>
  159.  
  160.  
  161.  
  162. <p>Marketing &amp; Communication Robotics</p>
  163.  
  164.  
  165.  
  166. <p>Stäubli Tec-Systems GmbH</p>
  167.  
  168.  
  169.  
  170. <p>95448 Bayreuth / DE</p>
  171.  
  172.  
  173.  
  174. <p>Phone: +49 (0)921 883 3212</p>
  175.  
  176.  
  177.  
  178. <p><a>E-</a>Mail : <a href="mailto:s.koban@staubli.com">s.koban@staubli.com</a></p>
  179.  
  180.  
  181.  
  182. <p><strong>About Stäubli</strong></p>
  183.  
  184.  
  185.  
  186. <p>Stäubli is a global industrial and mechatronic solution provider with four dedicated Divisions: Electrical Connectors, Fluid Connectors, Robotics and Textile, serving customers who aim to increase their productivity in many industrial sectors. Stäubli currently operates in 28 countries, with agents in 50 countries on four continents. Its global workforce of 6,000 shares a commitment to partnering with customers in nearly every industry to provide comprehensive solutions with long-term support. Originally founded in 1892 as a small workshop in Horgen/Zurich, Switzerland, today Stäubli is an international Group headquartered in Pfäffikon, Switzerland.</p>
  187.  
  188.  
  189.  
  190. <p><a href="https://www.staubli.com/global/en/home.html" target="_blank" rel="noopener">https://www.staubli.com/global/en/home.html</a></p>
  191.  
  192.  
  193.  
  194. <p><strong>About Stäubli Robotics</strong></p>
  195.  
  196.  
  197.  
  198. <p>Stäubli Robotics’ unique product portfolio contains 4 and 6 axis industrial robots, cobots, mobile robotics and Automated Guided Vehicles. The powerful, high precision solutions allow clients in many demanding industries to tackle the challenges of Industry 4.0 under specific manufacturing conditions.</p>
  199.  
  200.  
  201.  
  202. <p><a href="https://www.staubli.com/global/en/robotics.html" target="_blank" rel="noopener">Robotic automation for industrial applications | Stäubli </a><a href="https://www.linkedin.com/company/staubli-robotics/" target="_blank" rel="noopener">https://www.linkedin.com/company/staubli-robotics/</a></p>
  203. ]]></content:encoded>
  204. </item>
  205. <item>
  206. <title>Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report</title>
  207. <link>https://international-pharma.com/leading-cdmo-pci-pharma-services-releases-inaugural-comprehensive-esg-report/</link>
  208. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  209. <pubDate>Wed, 27 Mar 2024 15:18:03 +0000</pubDate>
  210. <category><![CDATA[News]]></category>
  211. <guid isPermaLink="false">https://international-pharma.com/?p=38763</guid>
  212.  
  213. <description><![CDATA[Highlights include environmental goals based on climate science, workforce empowerment, focus on local partnerships, and supply chain resiliency. PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social &#38; Governance (ESG) Report. A detailed overview of PCI’s multifaceted sustainability journey, the report showcases the strides taken [&#8230;]]]></description>
  214. <content:encoded><![CDATA[
  215. <p><strong><em>Highlights include environmental goals based on climate science, workforce empowerment, focus on local partnerships, and supply chain resiliency.</em></strong></p>
  216.  
  217.  
  218.  
  219. <p><strong>PCI Pharma Services</strong>, (“PCI”)<strong> </strong>a leading global contract development and manufacturing organization (CDMO), has released its first <a href="https://pci.com/wp-content/uploads/2024/03/PCI-Pharma-Services-ESG-Report-FY23.pdf?utm_source=External-News-Site&amp;utm_medium=Press-Release&amp;utm_campaign=ESG-2024" target="_blank" rel="noopener"><strong>Environmental, Social &amp; Governance (ESG) Report</strong></a>. A detailed overview of PCI’s multifaceted sustainability journey, the report showcases the strides taken from the program’s formal inception in 2021 through its 2023 fiscal year and lays out ambitious goals for continued progress along multiple fronts.</p>
  220.  
  221.  
  222. <div class="wp-block-image">
  223. <figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://international-pharma.com/wp-content/uploads/2024/03/PCI-Pharma-Services-Press-Release-Photo_ESG_PR-1024x683.jpg" alt="" class="wp-image-38764" srcset="https://international-pharma.com/wp-content/uploads/2024/03/PCI-Pharma-Services-Press-Release-Photo_ESG_PR-1024x683.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/PCI-Pharma-Services-Press-Release-Photo_ESG_PR-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/PCI-Pharma-Services-Press-Release-Photo_ESG_PR-768x512.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/PCI-Pharma-Services-Press-Release-Photo_ESG_PR-1536x1024.jpg 1536w, https://international-pharma.com/wp-content/uploads/2024/03/PCI-Pharma-Services-Press-Release-Photo_ESG_PR.jpg 1800w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></div>
  224.  
  225.  
  226. <p></p>
  227.  
  228.  
  229.  
  230. <p>The in-depth report discloses PCI&#8217;s performance, targets, and strategy to achieve nine identified impact categories, from sustainability-focused practices concerning carbon footprint, responsible waste management and eco-conscious procurement to people-first issues such as health and safety, community impact and DEI. Given its position as a world-class CDMO whose global customers and vendors number well into the thousands, PCI’s ESG initiatives are intended to purposefully impact the many local and global communities it interacts with, cares for and serves.  </p>
  231.  
  232.  
  233.  
  234. <p>True to this mindset, PCI Pharma’s ESG program is inherently inclusive and bottom-up. The report includes PCI’s approach to a <strong>Double Materiality Assessment</strong>, which gathers input from hundreds of employees as well as external stakeholders including customers, supplier partners, investors and community organizations. The purpose of this assessment is to identify those ESG elements important to and emphasized by all stakeholders and, from there, to focus on meaningful and measurable progress against those critical factors.</p>
  235.  
  236.  
  237.  
  238. <p>Encouragingly, the Double Materiality Assessment indicated that the majority of PCI’s ESG impact categories are in alignment with its stakeholders’ priorities. Even so, the assessment results were insightful and were taken into account to ensure long-term alignment between stakeholder priorities and PCI’s ESG strategy.</p>
  239.  
  240.  
  241.  
  242. <p>Other highlights from PCI’s ESG report include:</p>
  243.  
  244.  
  245.  
  246. <ul>
  247. <li><strong>Emission reduction targets</strong>. By 2030, PCI aims to<ul><li>Reduce Scope 1 and 2 Greenhouse Gas emissions by 40%</li></ul><ul><li>Cut its energy intensity by 50%</li></ul>
  248. <ul>
  249. <li>Purchase 100% of its energy from renewable sources</li>
  250. </ul>
  251. </li>
  252. </ul>
  253.  
  254.  
  255.  
  256. <p>Carbon footprint targets and strategy were developed in alignment to Science Based Targets. By 2045, PCI aims to achieve a Net-Zero carbon footprint across its entire supply chain.</p>
  257.  
  258.  
  259.  
  260. <ul>
  261. <li><strong>Water conservation. </strong>By 2030, PCI plans to reduce its global water consumption by 50% per cubic meter, and while the pharma sector’s cleanliness and sterility needs are inherently water-intensive, PCI remains committed to this ambitious goal.</li>
  262. </ul>
  263.  
  264.  
  265.  
  266. <ul>
  267. <li><strong>Waste management. </strong>By 2030, PCI targets non-hazardous waste intensity reduction by 33%, reduction of waste sent to landfills by 90%, and has plans in place to reach 100% recycling of recyclable waste.</li>
  268. </ul>
  269.  
  270.  
  271.  
  272. <p><br>* All environmental targets were calculated against a 2020 baseline.</p>
  273.  
  274.  
  275.  
  276. <ul>
  277. <li><strong>Community Impact. </strong>PCIhas established a formal giving-back strategy focused on year-over-year increases in employee participation and measurable community impact for each of its global sites and corporate functions. Activities on this front include identifying the greatest needs of local communities and partnering with relevant organizations; communicating volunteer opportunities and encouraging employees to create interest groups; and a novel program called the ESG Day Initiative, in which employees can log up to eight hours per year of company-sponsored volunteer activities across various categories.</li>
  278. </ul>
  279.  
  280.  
  281.  
  282. <ul>
  283. <li><strong>Organization-wide DEI.</strong> PCI remains dedicated to enhancing our inclusion and diversity measurements, with a particular focus on pay equity and balanced gender and ethnic representation throughout the organization, extending to levels of executive and board leadership. The company’s DEI efforts extend beyond operations and into the supply chain; with the Supplier Diversity Program, PCI is increasing support for businesses owned by women, minorities and vulnerable groups in the supply chain.</li>
  284. </ul>
  285.  
  286.  
  287.  
  288. <p>A healthcare service company at its core, PCI sees its approach to ESG as showcasing how the wellbeing of the planet and its people are intimately interconnected.</p>
  289.  
  290.  
  291.  
  292. <p>“Although we at PCI formally established our ESG Program in 2021, our ESG consciousness is by no means new,” said Salim Haffar, CEO of PCI Pharma Services. “As a responsible business, we have been evolving daily to align our commitments, culture, and performance with the wellbeing of humans, the planet and the communities we serve. As a team, we are learning and adapting to industry best practices, sharing lessons learned along the way, and building a strong foundation for a resilient future.”</p>
  293.  
  294.  
  295.  
  296. <p><strong>About PCI Pharma Services</strong></p>
  297.  
  298.  
  299.  
  300. <p>PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain), and over 6,000 employees working to bring life-changing therapies to patients.</p>
  301.  
  302.  
  303.  
  304. <p>Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives. For more information, visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpci.com%2F&amp;esheet=53636356&amp;newsitemid=20231019397849&amp;lan=en-US&amp;anchor=pci.com&amp;index=6&amp;md5=ac18861715fc4f6ce941d12b928bd44a" target="_blank" rel="noreferrer noopener">pci.com</a></p>
  305. ]]></content:encoded>
  306. </item>
  307. <item>
  308. <title>Navigate Pharma’s Future: Regional Partners of PHARMAP 2024</title>
  309. <link>https://international-pharma.com/navigate-pharmas-future-regional-partners-of-pharmap-2024/</link>
  310. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  311. <pubDate>Wed, 27 Mar 2024 13:16:48 +0000</pubDate>
  312. <category><![CDATA[News]]></category>
  313. <guid isPermaLink="false">https://international-pharma.com/?p=38444</guid>
  314.  
  315. <description><![CDATA[The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2024) brings together esteemed regional partners with the mission to transform the industry with green innovative solutions and cutting-edge technologies. The Congress takes place in Amsterdam, the Netherlands, on 22-23 April. This year, BGS Group welcomes the regional partners of PHARMAP 2024 to support the Congress and share [&#8230;]]]></description>
  316. <content:encoded><![CDATA[
  317. <p><a href="https://sh.bgs.group/1ej" target="_blank" rel="noopener"><em>The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2024)</em></a><em> brings together esteemed regional partners with the mission to transform the industry with green innovative solutions and cutting-edge technologies. The Congress takes place in Amsterdam, the Netherlands, on 22-23 April.</em></p>
  318.  
  319.  
  320. <div class="wp-block-image">
  321. <figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://international-pharma.com/wp-content/uploads/2024/03/Pharmap-2024-1024x683.jpg" alt="" class="wp-image-38445" srcset="https://international-pharma.com/wp-content/uploads/2024/03/Pharmap-2024-1024x683.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/Pharmap-2024-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/Pharmap-2024-768x512.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/Pharmap-2024-1536x1024.jpg 1536w, https://international-pharma.com/wp-content/uploads/2024/03/Pharmap-2024.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></div>
  322.  
  323.  
  324. <p></p>
  325.  
  326.  
  327.  
  328. <p>This year, BGS Group welcomes the regional partners of PHARMAP 2024 to support the Congress and share their commitment to a sustainable future and impactful medicines and solutions. Among the companies are MSD, Organon and Produlab Pharma, Johnson &amp; Johnson Innovative Medicine and Echo Pharmaceuticals.</p>
  329.  
  330.  
  331.  
  332. <p>On the first day of PHARMAP 2024, the executive opening panel about new models for pharma manufacturing and packaging gathers CEOs, CFOs, managing directors and board members for an exchange of ideas on the integration of green initiatives into manufacturing and packaging operations. Maria Romano, Supply Chain Management expert at MSD, joins the panel to share the keys for preparing a supply planning team for organisational transformations.</p>
  333.  
  334.  
  335.  
  336. <p>Among the speakers of the opening executive panel is also Dolf Kroep, Director of Supply Chain Management at Organon. The presentation covers Organon’s initiative to reconfigure its global supply network and to transform the way the healthcare company runs its supply chains.</p>
  337.  
  338.  
  339.  
  340. <p>On the second day of the Congress, Maurice Janssen, Senior Specialist Real Estate, Facility Management &amp; Sustainability at Organon, participates in the roundtable session that features an exchange of views on the facility design future. Maurice gives an overview of facility management worldwide and examples of sustainability, monitoring and saving energy.</p>
  341.  
  342.  
  343.  
  344. <p>The second day of the Congress is going to be finalised by the panel dedicated to pharmaceutical trends and market forecasts. Amin Qureishi, a Qualified Person /Responsible Person at Produlab Pharma, is going to share the sustainability initiatives of the company as a CMO. Produlab Pharma is an independent veterinary CMO and one-stop shop for registered liquid and semi-solid pharmaceuticals. The company also can support customers in all stages of development and registration all the way to production and delivery.</p>
  345.  
  346.  
  347.  
  348. <p>Furthermore, the Congress welcomes Johnson &amp; Johnson Innovative Medicine as the regional partner, that is ready to network and share views on the pharma sustainable future. The company’s approach includes integrating sustainable design solutions into product innovation processes, taking into account the environmental impacts throughout a product’s lifecycle.</p>
  349.  
  350.  
  351.  
  352. <p>Echo Pharmaceuticals has also recently joined PHARMAP 2024 as the regional partner. Based in the Netherlands, the company develops medicines and products from the active ingredients in cannabis, cannabinoids. The company uses various techniques for the extraction of the substances from plant material and purification and formulation. Echo Pharmaceuticals also develops various technologies for the delivery of these medicines.</p>
  353.  
  354.  
  355.  
  356. <p>Together with regional partners, PHARMAP 2024 aims to revolutionise the pharmaceutical landscape through sustainable advancements and next-generation technologies.</p>
  357.  
  358.  
  359.  
  360. <p>Be a part of PHARMAP 2024 and learn more about the regional partners and their solutions: <a href="https://sh.bgs.group/1ej" target="_blank" rel="noopener">https://sh.bgs.group/1ej</a></p>
  361. ]]></content:encoded>
  362. </item>
  363. <item>
  364. <title>Researchers identify group of biological markers found in high levels in TB patients</title>
  365. <link>https://international-pharma.com/researchers-identify-group-of-biological-markers-found-in-high-levels-in-tb-patients/</link>
  366. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  367. <pubDate>Wed, 27 Mar 2024 09:44:15 +0000</pubDate>
  368. <category><![CDATA[News]]></category>
  369. <guid isPermaLink="false">https://international-pharma.com/?p=38427</guid>
  370.  
  371. <description><![CDATA[According to the World Health Organization, TB is responsible for over one million annual deaths. Researchers from the National Institute for Health and Care Research’s (NIHR) Southampton Biomedical Research Centre have identified a group of biological markers of tuberculosis (TB) found in high levels among infected patients. Published in the&#160;Journal of Clinical Investigation Insight&#160;for World [&#8230;]]]></description>
  372. <content:encoded><![CDATA[
  373. <p>According to the World Health Organization, TB is responsible for over one million annual deaths.</p>
  374.  
  375.  
  376.  
  377. <p>Researchers from the National Institute for Health and Care Research’s (NIHR) Southampton Biomedical Research Centre have identified a group of biological markers of tuberculosis (TB) found in high levels among infected patients.</p>
  378.  
  379.  
  380.  
  381. <p>Published in the<em>&nbsp;Journal of Clinical Investigation Insight</em>&nbsp;for World TB Day (24 March 2024), findings from the study could advance a simple blood test to speed up the diagnosis of the infection.</p>
  382.  
  383.  
  384.  
  385. <p>According to the World Health Organization, TB is the world’s deadliest infectious disease, caused by a bacterium known as Mycobacterium tuberculosis, which is responsible for more than one million deaths each year.</p>
  386.  
  387.  
  388.  
  389. <p>Estimated to affect ten million people globally every year, the highly contagious and easily transmitted TB spreads through the air when infected people cough, sneeze or spit, often affecting the lungs.</p>
  390.  
  391.  
  392.  
  393. <p>Supported by the NIHR and the UK Medical Research Council, researchers collaborated with global experts, including those from the University of Cape Town in South Africa and Cayetano Heredia University in Peru.</p>
  394.  
  395.  
  396.  
  397. <p>Researchers used a novel technique to identify a group of six proteins that are highly accurate in pinpointing TB after studying proteins found in the blood of people with active TB in Africa and South America.</p>
  398.  
  399.  
  400.  
  401. <p>After comparing the biomarkers found in healthy people and patients with lung infections, researchers identified a total of 118 proteins that differed significantly between groups.</p>
  402.  
  403.  
  404.  
  405. <p>Researchers then narrowed down these proteins to six that could distinguish contagious patients with TB from people in good health or with lung conditions.</p>
  406.  
  407.  
  408.  
  409. <p>Dr Diana Garay-Baquero, study co-director, University of Southampton, commented: “The new markers we discovered are truly exciting. The important work now is to develop these into tests that can be used for the millions of people who are transmitting TB without knowing it.”</p>
  410.  
  411.  
  412.  
  413. <p>In February, the Bill &amp; Melinda Gates Foundation awarded PhaSER Biomedical $2.3m to accelerate drug discovery and development to combat the ‘big three’ infectious diseases: TB, malaria and HIV, as part of a three-year research programme.</p>
  414. ]]></content:encoded>
  415. </item>
  416. <item>
  417. <title>Francis Crick researchers target cancer cells’ ability to survive at low oxygen levels</title>
  418. <link>https://international-pharma.com/francis-crick-researchers-target-cancer-cells-ability-to-survive-at-low-oxygen-levels/</link>
  419. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  420. <pubDate>Wed, 27 Mar 2024 09:43:22 +0000</pubDate>
  421. <category><![CDATA[News]]></category>
  422. <guid isPermaLink="false">https://international-pharma.com/?p=38425</guid>
  423.  
  424. <description><![CDATA[LDHA and GOT1 enzymes successfully targeted and halted energy production in hard-to-reach cancer cells. Researchers from the Francis Crick Institute have revealed how cancer cells survive after being cut off from a supply of oxygen, which could potentially help prevent cancer from becoming resistant to therapy. Published in the&#160;EMBO Journal, the study revealed that inhibiting [&#8230;]]]></description>
  425. <content:encoded><![CDATA[
  426. <p>LDHA and GOT1 enzymes successfully targeted and halted energy production in hard-to-reach cancer cells.</p>
  427.  
  428.  
  429.  
  430. <p>Researchers from the Francis Crick Institute have revealed how cancer cells survive after being cut off from a supply of oxygen, which could potentially help prevent cancer from becoming resistant to therapy.</p>
  431.  
  432.  
  433.  
  434. <p>Published in the&nbsp;<em>EMBO Journal</em>, the study revealed that inhibiting two enzymes, LDHA and GOT1, could target hard-to-reach cancer cells by stopping their energy production.</p>
  435.  
  436.  
  437.  
  438. <p>Coordinated by a protein known as HIF1α, which turns on the activity of genes, most cells can survive low oxygen levels as they adapt by changing which proteins they produce to increase energy through different processes than in normal oxygen levels.</p>
  439.  
  440.  
  441.  
  442. <p>Researchers found that a process known as glycolysis, which breaks down glucose to produce energy, increases within three hours of the cancer cells being deprived of oxygen.</p>
  443.  
  444.  
  445.  
  446. <p>After genetically modifying the cells to stop producing HIF1α and depriving them of oxygen, glycolysis still increased, revealing that LDHA and GOT1 worked together to make enough levels of NAD+, which controls and increases the rate of glycolysis in the cells, acting as reserves for a state of low oxygen.</p>
  447.  
  448.  
  449.  
  450. <p>After blocking the action of LDHA and GOT1 and inhibiting both enzymes together, the researchers revealed the process effectively killed cancer cells in low oxygen compared to normal oxygen levels or by targeting the enzymes individually.</p>
  451.  
  452.  
  453.  
  454. <p>The findings highlight LDHA and GOT1 as potentially promising targets for treatment and are being further investigated via the EPSRC Prosperity Partnership.</p>
  455.  
  456.  
  457.  
  458. <p>Dimitrios Anastasiou, group leader, Cancer Metabolism Laboratory, the Crick, said: “We’ve looked at the acute needs of cells due to a changing environment.</p>
  459.  
  460.  
  461.  
  462. <p>“Our research highlights a vulnerability for cancer cells in the first few hours of becoming cut off from oxygen.”</p>
  463.  
  464.  
  465.  
  466. <p>The Crick’s Fiona Grimm and first author said: “By blocking these enzymes in oxygen-deprived cells where they are needed most, we can hopefully target these cells before they adapt to low oxygen and become hard to reach or resistant to therapy.”</p>
  467. ]]></content:encoded>
  468. </item>
  469. <item>
  470. <title>Skin biopsy test detects abnormalities of key biomarker in neurodegenerative disorders</title>
  471. <link>https://international-pharma.com/skin-biopsy-test-detects-abnormalities-of-key-biomarker-in-neurodegenerative-disorders/</link>
  472. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  473. <pubDate>Wed, 27 Mar 2024 09:42:18 +0000</pubDate>
  474. <category><![CDATA[News]]></category>
  475. <guid isPermaLink="false">https://international-pharma.com/?p=38423</guid>
  476.  
  477. <description><![CDATA[Estimated to affect 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders. Neurologists from the Beth Israel Deaconess Medical Center (BIDMC) have revealed that a simple skin biopsy test could detect abnormal amounts of alpha-synuclein, a key biomarker of Parkinson’s disease (PD), as well as other neurodegenerative disorders. Published in the&#160;Journal of American [&#8230;]]]></description>
  478. <content:encoded><![CDATA[
  479. <p>Estimated to affect 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders.</p>
  480.  
  481.  
  482.  
  483. <p>Neurologists from the Beth Israel Deaconess Medical Center (BIDMC) have revealed that a simple skin biopsy test could detect abnormal amounts of alpha-synuclein, a key biomarker of Parkinson’s disease (PD), as well as other neurodegenerative disorders.</p>
  484.  
  485.  
  486.  
  487. <p>Published in the&nbsp;<em>Journal of American Medical Association&nbsp;</em>and sponsored by the National Institute of Health, the results of the study could help physicians make more accurate diagnoses and improve clinical trials for alpha-synuclein targeting investigational drugs.</p>
  488.  
  489.  
  490.  
  491. <p>Affecting an estimated 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders: PD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and pure autonomic failure (PAF), which share a common pathologic lesion called phosphorylated alpha-synuclein (P-SYN).</p>
  492.  
  493.  
  494.  
  495. <p>Building on a previous BIDMC study in 2023, which demonstrated that skin biopsies could distinguish between PD and MSA, which both have similar prognoses, the Synuclein-One Study enrolled 428 people aged 40 to 99 years old, with a clinical diagnosis of one of the four synucleinopathies with no previous history of neurodegenerative disease who underwent three 3mm skin punch biopsies taken from the neck, knee and ankle.</p>
  496.  
  497.  
  498.  
  499. <p>Results found that 93% of PD patients demonstrated a positive skin biopsy for P-SYN, while those with DLB and MSA tested 96% and 98% positive, respectively.</p>
  500.  
  501.  
  502.  
  503. <p>Additionally, 100% of patients with PAF were positive for P-SYN, while just over 3% of those in the control group tested positive for the abnormal protein.</p>
  504.  
  505.  
  506.  
  507. <p>Researchers hope that the findings from the study will help accelerate drug development for synucleinopathies.</p>
  508.  
  509.  
  510.  
  511. <p>Christopher Gibbons, neurologist at BIDMC and professor of neurology at Harvard Medical School (HMS), said: “This… study demonstrated how we can more objectively identify the underlying pathology of synucleinopathies and offer better diagnostic answers.”</p>
  512.  
  513.  
  514.  
  515. <p>Roy Freeman, director, BIDMC’s Center for Autonomic and Peripheral Nerve Disorders and professor of neurology at HMS, said: “Identifying the relevant biomarker… and tracking it over the course of a clinical trial is an essential component of drug development in the neurodegeneration field.”</p>
  516. ]]></content:encoded>
  517. </item>
  518. <item>
  519. <title>Four international teams awarded £4.7m to investigate heart and circulatory diseases</title>
  520. <link>https://international-pharma.com/four-international-teams-awarded-4-7m-to-investigate-heart-and-circulatory-diseases/</link>
  521. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  522. <pubDate>Wed, 27 Mar 2024 09:41:24 +0000</pubDate>
  523. <category><![CDATA[News]]></category>
  524. <guid isPermaLink="false">https://international-pharma.com/?p=38421</guid>
  525.  
  526. <description><![CDATA[These types of conditions are responsible for 25% of all UK deaths and affect 7.6 million people nationally. The British Heart Foundation (BHF), the Dutch Heart Foundation and the German Centre for Cardiovascular Research have awarded four international research teams £4.7m for research in heart and circulatory diseases. Over four years, researchers from the UK, [&#8230;]]]></description>
  527. <content:encoded><![CDATA[
  528. <p>These types of conditions are responsible for 25% of all UK deaths and affect 7.6 million people nationally.</p>
  529.  
  530.  
  531.  
  532. <p>The British Heart Foundation (BHF), the Dutch Heart Foundation and the German Centre for Cardiovascular Research have awarded four international research teams £4.7m for research in heart and circulatory diseases.</p>
  533.  
  534.  
  535.  
  536. <p>Over four years, researchers from the UK, Germany and the Netherlands will drive breakthroughs in the detection, diagnosis and treatment of these conditions.</p>
  537.  
  538.  
  539.  
  540. <p>Responsible for 25% of all deaths in the UK, heart and circulatory diseases affect around 7.6 million people nationally.</p>
  541.  
  542.  
  543.  
  544. <p>Researchers from the University of Bristol, Maastricht University Medical Center, the University of Birmingham, Charité-Universitätsmedizin Berlin, Amsterdam University Medical Center (Amsterdam UMC), the University of Cambridge, Universiteit Leiden, King’s College London (KCL) and University Medical Center Goettingen (UMC Goettingen) have been selected to be funded through the International Cardiovascular Research Partnership Awards.</p>
  545.  
  546.  
  547.  
  548. <p>The projects will investigate different areas, including the use of placentas to understand heart and circulatory disease risks in women who develop high blood pressure or pre-eclampsia during pregnancy, as well as the role of heart muscle fibres in hypertrophic cardiomyopathy, an inherited disease that affects the heart’s ability to pump blood.</p>
  549.  
  550.  
  551.  
  552. <p>Investigators from Cambridge and the Netherlands plan to unlock the potential of immune cells to combat atherosclerosis, inflammation within arteries that makes plaques grow, to understand more about the effects of an anti-inflammatory drug called interleukin-2.</p>
  553.  
  554.  
  555.  
  556. <p>Principal investigators Dr Joseph Burgoyne from KCL, Dr Lukas Cyganek from UMC Goettingen and Amsterdam UMC’s Dr Monika Gladka have been awarded almost £450,000 to investigate how faulty genes that cause dilated cardiomyopathy – when the muscular walls of the heart stretch – weaken the function of heart muscles, to “gain a better understanding of the key processes that cause this condition” and to “aid the development of new, more advanced therapies,” explained Burgoyne.</p>
  557.  
  558.  
  559.  
  560. <p>Professor Metin Avkiran, associate medical director at BHF, commented: “Through this funding, we can help… cement collaborations between future research leaders that will continue to reap rewards long after these projects have finished.”</p>
  561. ]]></content:encoded>
  562. </item>
  563. <item>
  564. <title>Innovate UK awards ten projects over £6m to develop new clinical tools for dementia</title>
  565. <link>https://international-pharma.com/innovate-uk-awards-ten-projects-over-6m-to-develop-new-clinical-tools-for-dementia/</link>
  566. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  567. <pubDate>Wed, 27 Mar 2024 09:40:28 +0000</pubDate>
  568. <category><![CDATA[News]]></category>
  569. <guid isPermaLink="false">https://international-pharma.com/?p=38419</guid>
  570.  
  571. <description><![CDATA[Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year. Innovate UK has awarded ten new projects over £6m in funding to identify, develop and commercialise biomarker clinical tools and technologies for dementia and neurodegeneration. Through Innovate UK’s Small Business Research Initiative, the competition will aid in [&#8230;]]]></description>
  572. <content:encoded><![CDATA[
  573. <p>Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year.</p>
  574.  
  575.  
  576.  
  577. <p>Innovate UK has awarded ten new projects over £6m in funding to identify, develop and commercialise biomarker clinical tools and technologies for dementia and neurodegeneration.</p>
  578.  
  579.  
  580.  
  581. <p>Through Innovate UK’s Small Business Research Initiative, the competition will aid in enhancing clinical trials and precision therapies for patients living with dementia.</p>
  582.  
  583.  
  584.  
  585. <p>Estimated to affect 850,000 people in the UK, dementia is a general term for the impaired ability to remember, think or make decisions, which is economically responsible to cost £23bn a year.</p>
  586.  
  587.  
  588.  
  589. <p>Alzheimer’s disease, the most common form of dementia, affects one in 14 people over the age of 65 and one in six people over the age of 80.</p>
  590.  
  591.  
  592.  
  593. <p>In alignment with the Dame Barbara Windsor Dementia Mission, a government-led effort to develop new precision dementia therapies and solutions in the UK, the competition aims to address the complexities of dementia and will empower organisations to develop customised tools using state-of-the-art technologies and repurposed innovations.</p>
  594.  
  595.  
  596.  
  597. <p>Dame Barbara Windsor Dementia Mission co-chairs Nadeem Sarwar and Hilary Evans said: “The… technologies being funded… align with our focus on accelerating biomarker and clinical trial innovation, underpinned by scalable data sciences.”</p>
  598.  
  599.  
  600.  
  601. <p>By addressing the urgent need for improved clinical tools capable of identifying suitable patients for clinical trials and tailoring treatments, the ten projects could revolutionise dementia therapy while leveraging UK life science’s expertise.</p>
  602.  
  603.  
  604.  
  605. <p>The projects selected involve Cumulus Neuroscience, Cortirio, Cambridge Vision Technology, IXICO Technologies, the University of Nottingham, Quantified Imaging, Esya, Fraunhofer UK Research, Cfdx and Occuity and will cultivate artificial intelligence, digital biomarkers, labelling MRI, liquid biopsy and more.</p>
  606.  
  607.  
  608.  
  609. <p>Dr Stella Peace, executive director, healthy living and agriculture domain, Innovate UK, said: “This investment marks a significant step forward in our collective efforts to manage and eventually overcome the challenges posed by dementia” and “will play a pivotal role in shaping the future of dementia therapy, making life better for all”.</p>
  610. ]]></content:encoded>
  611. </item>
  612. <item>
  613. <title>Researchers reveal protein found in human sweat could protect against Lyme disease</title>
  614. <link>https://international-pharma.com/researchers-reveal-protein-found-in-human-sweat-could-protect-against-lyme-disease/</link>
  615. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  616. <pubDate>Wed, 27 Mar 2024 09:38:01 +0000</pubDate>
  617. <category><![CDATA[News]]></category>
  618. <guid isPermaLink="false">https://international-pharma.com/?p=38417</guid>
  619.  
  620. <description><![CDATA[The bacterial infection transmitted by ticks affects nearly half a million people in the US every year. Researchers from the Massachusetts Institute of Technology and the University of Helsinki in Finland have discovered a protein found in human sweat that can protect against Lyme disease. As published in&#160;Nature Communications, around one-third of the population was [&#8230;]]]></description>
  621. <content:encoded><![CDATA[
  622. <p>The bacterial infection transmitted by ticks affects nearly half a million people in the US every year.</p>
  623.  
  624.  
  625.  
  626. <p>Researchers from the Massachusetts Institute of Technology and the University of Helsinki in Finland have discovered a protein found in human sweat that can protect against Lyme disease.</p>
  627.  
  628.  
  629.  
  630. <p>As published in&nbsp;<em>Nature Communications</em>, around one-third of the population was found to carry a genetic variation of SCGB1D2, a secretoglobin associated with Lyme disease, a bacterial infection transmitted by ticks.</p>
  631.  
  632.  
  633.  
  634. <p>Affecting nearly half a million people in the US annually, Lyme disease is often caused by a bacterium called Borrelia burgdorferi and can cause symptoms such as fever, headache and fatigue.</p>
  635.  
  636.  
  637.  
  638. <p>Previously, researchers from Stanford University ran a genome-wide association study (GWAS) on a Finnish dataset containing genome sequences of 410,000 people, including 7,000 patients with Lyme disease and revealed three links to Lyme disease, including two already-identified hits in immune molecules and a third, unidentified hit being SCGB1D2.</p>
  639.  
  640.  
  641.  
  642. <p>Produced primarily by cells in the sweat glands, secretoglobins are a group of proteins found in tissues that line the lungs and other organs that play a role in immune responses to infection.</p>
  643.  
  644.  
  645.  
  646. <p>In an effort to determine how this protein influences Lyme disease, the new study created normal and mutated versions of SCGB1D2 and exposed them to lab-grown Borrelia burgdorferi.</p>
  647.  
  648.  
  649.  
  650. <p>Researchers found that the normal version of SCGB1D2 inhibited the growth of the bacterium, while the mutated version of the protein required twice as much SCGB1D2 to suppress bacterial growth.</p>
  651.  
  652.  
  653.  
  654. <p>After injecting exposed bacteria with either the normal or mutated variant of SCGB1D2 into mice, the team found that mice injected with the bacteria exposed to the mutant protein became infected with Lyme disease, while mice injected with bacteria exposed to the normal version of SCGB1D2 did not.</p>
  655.  
  656.  
  657.  
  658. <p>Estonian researchers later replicated these results using data from 210,000 people, including 18,000 with Lyme disease, from the Estonian Biobank.</p>
  659.  
  660.  
  661.  
  662. <p>Researchers plan to investigate whether SCGB1D2 could prevent infection from Borrelia burgdorferi and explore the protein’s potential as a treatment for infections that are antibiotic-resistant.</p>
  663. ]]></content:encoded>
  664. </item>
  665. <item>
  666. <title>Woolcool</title>
  667. <link>https://international-pharma.com/woolcool-2/</link>
  668. <dc:creator><![CDATA[theArchitect]]></dc:creator>
  669. <pubDate>Tue, 26 Mar 2024 16:17:43 +0000</pubDate>
  670. <category><![CDATA[Company profile]]></category>
  671. <category><![CDATA[T-Z]]></category>
  672. <guid isPermaLink="false">https://international-pharma.com/?p=38407</guid>
  673.  
  674. <description><![CDATA[Insulated packaging pioneers Woolcool® was launched in 2008 and offers superior insulated packaging for the transportation of temperature-sensitive goods using the extraordinary properties of 100% sheep&#8217;s wool. As two-time Queen’s Award winners, Woolcool® provide market-leading temperature-controlled packaging, which relies on expertly balancing conditions inside and outside of our products &#8211; whether that’s an insulated box [&#8230;]]]></description>
  675. <content:encoded><![CDATA[
  676. <p><em>Insulated packaging pioneers</em></p>
  677.  
  678.  
  679.  
  680. <p>Woolcool® was launched in 2008 and offers superior insulated packaging for the transportation of temperature-sensitive goods using the extraordinary properties of 100% sheep&#8217;s wool.</p>
  681.  
  682.  
  683. <div class="wp-block-image">
  684. <figure class="alignleft size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://international-pharma.com/wp-content/uploads/2024/03/02870_WOOLCOOL_COMPANY_PROFILE_RGB_300x250px_01.jpg" alt="" class="wp-image-38408"/></figure></div>
  685.  
  686.  
  687. <p><strong>As two-time Queen’s Award winners, Woolcool® provide market-leading temperature-controlled packaging, which relies on expertly balancing conditions inside and outside of our products &#8211; whether that’s an insulated box or a smaller package, using the remarkable insulation properties of 100% sheep’s wool.</strong></p>
  688.  
  689.  
  690.  
  691. <p></p>
  692.  
  693.  
  694.  
  695. <p>That means making sure each insulated box or package is created to strike the right balance in terms of its constituent parts, from the liner to the outer packaging and the ice packs inside. But, as a business, we also strive to find balance in so many other ways. We try our best to ensure our team enjoys a healthy work-life balance. As a certified B-Corp, we work to ensure that we balance the need to make a profit as a business with the impact of what we do on the community, wider society and the planet. And crucially, as a business founded on a sustainable ethos, we always consider the ecological impact of our work, from broader business principles to each individual insulated box or packaging option we create for our clients and partners.</p>
  696.  
  697.  
  698. <div class="wp-block-image">
  699. <figure class="aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="682" src="https://international-pharma.com/wp-content/uploads/2024/03/woolcool_pharma_box_04-1024x682.jpg" alt="" class="wp-image-38410" srcset="https://international-pharma.com/wp-content/uploads/2024/03/woolcool_pharma_box_04-1024x682.jpg 1024w, https://international-pharma.com/wp-content/uploads/2024/03/woolcool_pharma_box_04-300x200.jpg 300w, https://international-pharma.com/wp-content/uploads/2024/03/woolcool_pharma_box_04-768x512.jpg 768w, https://international-pharma.com/wp-content/uploads/2024/03/woolcool_pharma_box_04.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></div>
  700.  
  701.  
  702. <p></p>
  703.  
  704.  
  705.  
  706. <p>When it comes to materials, balance is everything. As the founder of the Natural Materials Association, we are passionate advocates of finding better ways to use the materials created by Mother Nature. 100% sheep’s wool is a great example of a natural material that outperforms manmade equivalents such as polystyrene. Wool is natural, recyclable, compostable, biodegradable, renewable, reusable and abundant. It is lighter and takes up less space than manmade insulators, and so has a smaller carbon footprint and so cuts supply chain transport costs.</p>
  707.  
  708.  
  709. <div class="wp-block-image">
  710. <figure class="alignright size-full is-resized"><img loading="lazy" decoding="async" width="900" height="696" src="https://international-pharma.com/wp-content/uploads/2024/03/woolcool-pharma-image-cut-away.png" alt="" class="wp-image-38411" style="width:381px;height:auto" srcset="https://international-pharma.com/wp-content/uploads/2024/03/woolcool-pharma-image-cut-away.png 900w, https://international-pharma.com/wp-content/uploads/2024/03/woolcool-pharma-image-cut-away-300x232.png 300w, https://international-pharma.com/wp-content/uploads/2024/03/woolcool-pharma-image-cut-away-768x594.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure></div>
  711.  
  712.  
  713. <p>Yet, despite the scientifically proven properties of wool, we still take a balanced approach when we design each insulated box or packaging solution around our wool insulation liners. That means considering the amount of cardboard, the thickness and strength of the outer packaging and the ice packs inside each insulated box, along with the separators needed to protect the contents. Extra consideration has to be given to the use of plastics or glass – the balance to be struck between the ecological credential of the packaging solution and its efficiency.</p>
  714.  
  715.  
  716.  
  717. <p>So, whatever your needs, we have the expertise to advise and help you make the decisions that strike the right balance. Our mantra is and will always be, the right materials, for the right application, fully researched from beginning to end of life.</p>
  718.  
  719.  
  720.  
  721. <p>Woolcool®</p>
  722.  
  723.  
  724.  
  725. <p>Units 1a + 1b Tungsten Park, Opal Way,</p>
  726.  
  727.  
  728.  
  729. <p>Stone, Staffordshire ST15 0NN</p>
  730.  
  731.  
  732.  
  733. <p>01785 262030</p>
  734.  
  735.  
  736.  
  737. <p><a href="mailto:sales@woolcool.com">sales@woolcool.com</a></p>
  738.  
  739.  
  740.  
  741. <p><a href="http://www.woolcool.com/" target="_blank" rel="noopener">www.woolcool.com</a><strong></strong></p>
  742. ]]></content:encoded>
  743. </item>
  744. </channel>
  745. </rss>
  746.  

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

  1. Download the "valid RSS" banner.

  2. Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)

  3. Add this HTML to your page (change the image src attribute if necessary):

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=https%3A//international-pharma.com/feed/

Copyright © 2002-9 Sam Ruby, Mark Pilgrim, Joseph Walton, and Phil Ringnalda